Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
Gloria IacoboniVíctor NavarroAna África Martín-LópezMarion SubkleweMi KwonKatarzyna Aleksandra JalowiecPaula AmatJuan Luis Reguera-OrtegaLaura GallurViktoria BlumenbergSara Gutiérrez-HerreroClaire RoddieAna BenzaquénJavier Delgado-SerranoMario Andrés Sánchez-SalinasRebeca BailénCecilia CarpioLucia López-CorralRafael HernaniMariana Bastos-OreiroMaeve A O'ReillyLourdes Martín-MartínMarion SubklewePere BarbaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Recent bendamustine exposure before apheresis was associated with negative treatment outcomes after CD19-targeted CAR T-cell therapy and should be therefore avoided in CAR T-cell candidates.